Status:
NOT_YET_RECRUITING
Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)
Lead Sponsor:
Fudan University
Conditions:
Limited Stage Small Cell Lung Cancer
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
ADRIATIC study explored the benefits of immune maintenance therapy after LS-SCLC radiotherapy and chemotherapy. In the presence of immunotherapy, is it necessary to increase the dosage of radiotherapy...
Eligibility Criteria
Inclusion
- Sign written informed consent before implementing any experimental procedures;
- Age range: 18-80 years old;
- Pathological diagnosis of small cell lung cancer;
- Limited stage;
- ECOG PS 0-1；
- Receive ≤ 2 rounds of chemotherapy or chemotherapy plus immunotherapy;
- Expected survival time\>3 months;
Exclusion
- Progress after 2 induction treatments;
- Severe emphysema, interstitial changes in the lungs, COPD patients;
- Resting blood oxygen\<93;
- Have a history of other malignant tumors and have received chemotherapy in the past 3 years;
- History of chest radiotherapy;
Key Trial Info
Start Date :
April 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2027
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06943235
Start Date
April 30 2025
End Date
December 30 2027
Last Update
April 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China